PRODUCTS & INNOVATION
FREESTYLE LIBRE SYSTEM POISED FOR BROADER REACH
New data show Abbott's CGM system has similar outcomes to adding insulin.
Jun 13 2020
The market could potentially expand for Abbott's world-leading1 FreeStyle Libre portfolio thanks to new data showing that the continuous glucose monitor (CGM) benefits people with type 2 diabetes regardless of whether or not they use insulin. These data were presented June 13 at the American Diabetes Association (ADA) 80th Scientific Sessions.
Historically, studies on Abbott's CGM technology focused on people with diabetes who use insulin multiple times a day.
This retrospective study2 looked at people with diabetes who take long-acting insulin, which requires fewer injections per day and those who don’t use insulin at all. The study found that both groups of people benefited greatly from using Abbott’s FreeStyle Libre system.
Overall, the study2 found that peoples’ HbA1c levels dropped 0.8% (from 8.5% to 7.7%) six months after starting to use the FreeStyle Libre system and decreased 0.6% (from 8.5% to 7.9%) after one year of using Abbott's CGM technology.
The HbA1c level reflects a person's mean glucose concentration over the past approximately 8 to 12 weeks.3 The ADA's recommended A1c goal for adults is 7%.4
"These data highlight how use of Abbott's continuous glucose monitor could be game-changing for people beyond intensive insulin users, translating to broader use of the technology to benefit all those living with diabetes, no matter where they are in the spectrum of care," said Dr. Eden Miller, one of the study authors and a family practice physician at High Lakes Health Care in Oregon.
Key findings of separate late-breaking abstracts
Two additional late-breaking results also assessed the impact of FreeStyle Libre use among people with type 2 diabetes who are not using intensive insulin therapy (such as bolus insulin).
These are the key findings:
"These new data emphasize the power of the FreeStyle Libre system to change countless lives among the millions of people with diabetes," said Mahmood Kazemi, M.D., divisional vice president, global medical and scientific affairs and chief medical officer, Diabetes Care, Abbott.
Get more details on the studies presented at the ADA Scientific Sessions.
1. Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
2. Miller, Brandner et al. HbA1c Reduction After Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Non-Insulin Therapy.
3. Mayo Clinic, Test ID: HBA1C.
4. American Diabetes Association. A1C and eAG. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/a1c/.
5. Wright et al. HbA1c Reduction Associated with a FreeStyle Libre® System in People with Type 2 Diabetes Not on Bolus Insulin Therapy.
6. Miller et al. FreeStyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes Without Bolus Insulin.
INDICATIONS AND IMPORTANT SAFETY INFORMATION
FreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.
CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.
Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.
Freestyle Libre 2: Next-Gen CGM is Here
Abbott Adds to Structural Heart Tech
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.